GR3004461T3 - - Google Patents

Info

Publication number
GR3004461T3
GR3004461T3 GR920400827T GR920400827T GR3004461T3 GR 3004461 T3 GR3004461 T3 GR 3004461T3 GR 920400827 T GR920400827 T GR 920400827T GR 920400827 T GR920400827 T GR 920400827T GR 3004461 T3 GR3004461 T3 GR 3004461T3
Authority
GR
Greece
Prior art keywords
cycloalkylamino
chem
bone
esters
integer
Prior art date
Application number
GR920400827T
Other languages
Greek (el)
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GR3004461T3 publication Critical patent/GR3004461T3/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3839Polyphosphonic acids
    • C07F9/3873Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40Esters thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40Esters thereof
    • C07F9/4003Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4025Esters of poly(thio)phosphonic acids
    • C07F9/405Esters of poly(thio)phosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
GR920400827T 1988-01-20 1992-04-29 GR3004461T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP1165688 1988-01-20

Publications (1)

Publication Number Publication Date
GR3004461T3 true GR3004461T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1993-03-31

Family

ID=11784011

Family Applications (1)

Application Number Title Priority Date Filing Date
GR920400827T GR3004461T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1988-01-20 1992-04-29

Country Status (14)

Country Link
US (2) US4970335A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0325482B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR970005179B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1022630C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE74361T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU615711B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA1339805C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE68901097D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK174744B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2032105T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (1) GR3004461T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HU202243B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IE (1) IE60477B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PH (1) PH26819A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1339805C (en) * 1988-01-20 1998-04-07 Yasuo Isomura (cycloalkylamino)methylenebis(phosphonic acid) and medicines containing the same as an active
IE912115A1 (en) * 1990-06-25 1992-01-01 Takeda Chemical Industries Ltd Bisphosphonic acid derivatives, their production and use
US5073339A (en) * 1990-08-23 1991-12-17 W. R. Grace & Co. - Conn Method of inhibiting corrosion and scale formation in aqueous systems
EP0491374B1 (en) * 1990-12-19 1996-01-31 Takeda Chemical Industries, Ltd. Bisphosphonic acid derivatives, their production and use
AU642336B2 (en) * 1991-02-07 1993-10-14 Kaken Pharmaceutical Co., Ltd. Bisphosphonic acid derivatives, their intermediates and bone resorption inhibitors containing them as active ingredients
EP0590009B1 (en) * 1991-06-19 1998-03-18 PHARMACIA & UPJOHN COMPANY Dialkyl (dialkoxyphosphinyl)methyl phosphates as anti-inflammatory agents
JPH05194563A (ja) * 1991-07-12 1993-08-03 Hoechst Ag 置換アミノエタン−1,1−ビスホスホン酸およびアミノエタン−1,1−アルキルホスフィノホスホン酸
EP0541037A3 (en) * 1991-11-06 1997-02-26 Takeda Chemical Industries Ltd Squalene synthetase inhibitory composition and use thereof
US5391743A (en) * 1992-05-29 1995-02-21 Procter & Gamble Pharmaceuticals, Inc. Quaternary nitrogen-containing phosphonate compounds, pharmaceutical compositions, and methods of treating abnormal calcium and phosphate metabolism and methods of treating and preventing dental calculus and plaque
US6406714B1 (en) 1992-12-02 2002-06-18 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids
US5358941A (en) 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
US6399592B1 (en) 1992-12-23 2002-06-04 Merck & Co., Inc. Bishphosphonate/estrogen synergistic therapy for treating and preventing bone loss
FR2703590B1 (fr) * 1993-04-05 1995-06-30 Sanofi Elf Utilisation de derives d'acide bisphosphonique pour la preparation de medicaments destines a favoriser la reparation osseuse .
US5854227A (en) * 1994-03-04 1998-12-29 Hartmann; John F. Therapeutic derivatives of diphosphonates
US20010007863A1 (en) * 1998-06-18 2001-07-12 Merck & Co., Inc. Wet granulation formulation for bisphosphonic acids
JPH11511041A (ja) 1995-06-06 1999-09-28 メルク エンド カンパニー インコーポレーテッド 整形外科的埋め込み装置の無菌性動揺を防止するビスホスホネートセメント組成物
US20030096760A1 (en) * 1997-03-10 2003-05-22 Smithklinebeecham Corporation Method of antagonizing the human SRC SH2 domain
IT1303672B1 (it) 1998-07-28 2001-02-23 Nicox Sa Sali nitrati di farmaci attivi nei disordini ossei
AR024462A1 (es) 1999-07-01 2002-10-02 Merck & Co Inc Tabletas farmaceuticas
KR20020059790A (ko) * 1999-11-25 2002-07-13 오노다 마사요시 치주병 치료제
US6677320B2 (en) 2000-01-20 2004-01-13 Hoffmann-La Roches Inc. Parenteral bisphosphonate composition with improved local tolerance
TWI349553B (en) * 2001-12-21 2011-10-01 Procter & Gamble Kit and use of bisphosphonate for treating high bone turnover
US20050070504A1 (en) * 2001-12-21 2005-03-31 The Procter & Gamble Co. Risedronate compositions and their methods of use
EP1469860A4 (en) * 2002-01-24 2005-09-07 Yissum Res Dev Co ANTICANCER COMBINATION AND USE THEREOF
PT1506041E (pt) * 2002-05-10 2007-12-28 Hoffmann La Roche Ácido ibandrónico para o tratamento e a prevenção da osteoporose
AU2003233731A1 (en) * 2002-06-06 2003-12-22 Xavier Billot 1,5-disubstituted imidazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of eye and bone diseases
AU2003258433A1 (en) * 2002-08-28 2004-03-19 Merck Frosst Canada Ltd Oxazolidin-2-one and thiazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of glaucoma
PT1596870E (pt) 2002-12-20 2007-10-15 Hoffmann La Roche Formulação com uma dose elevada de ibandronato
CN1839114A (zh) 2003-08-21 2006-09-27 默克弗罗斯特加拿大有限公司 组织蛋白酶半胱氨酸蛋白酶抑制剂
AU2004273672A1 (en) * 2003-09-19 2005-03-31 Wisconsin Alumni Research Foundation Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and a bisphosphonate
US20050261250A1 (en) * 2004-05-19 2005-11-24 Merck & Co., Inc., Compositions and methods for inhibiting bone resorption
CA2566798A1 (en) 2004-05-24 2005-12-08 The Procter & Gamble Company Enteric solid oral dosage form of bisphosphonate containing a chelating agent
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
AU2006302797B2 (en) 2005-03-02 2012-02-02 Merck Canada Inc. Composition for inhibition of cathepsin K
WO2006102117A1 (en) * 2005-03-17 2006-09-28 Elan Pharma International Limited Nanoparticulate biphosphonate compositions
US20110015158A1 (en) 2007-12-11 2011-01-20 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
BRPI0821090B8 (pt) 2007-12-21 2021-05-25 Ligand Pharm Inc moduladores seletivos de receptores de androgênio (sarms) e uso do mesmo
US20090181138A1 (en) 2008-01-11 2009-07-16 David Howard Process for producing precooked bacon slices
FR2954320B1 (fr) 2009-12-17 2012-06-15 Cll Pharma Composition pharmaceutique orale suprabiodisponible contenant un acide biphosphonique ou un de ses sels
US8791162B2 (en) 2011-02-14 2014-07-29 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
GB201200868D0 (en) 2012-01-19 2012-02-29 Depuy Int Ltd Bone filler composition
WO2015051479A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
CN105593230B (zh) 2013-10-08 2018-07-06 默沙东公司 组织蛋白酶半胱氨酸蛋白酶抑制剂
WO2015120580A1 (en) 2014-02-11 2015-08-20 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
PL407922A1 (pl) 2014-04-16 2015-10-26 Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Odpowiedzialnością Nowe bisfosfoniany i ich zastosowanie
BR112016027778A2 (pt) 2014-05-30 2017-08-15 Pfizer Usos de derivados de carbonitrila, sua combinação e sua composição farmacêutica
BR112021020864A2 (pt) 2019-04-19 2021-12-14 Ligand Pharm Inc Formas cristalinas e métodos de produção de formas cristalinas de um composto
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1958123C3 (de) * 1969-11-19 1978-09-28 Henkel Kgaa, 4000 Duesseldorf Verfahren zur Herstellung von 1 -Aminoalkan-1,1 -diphosphonsäuren oder deren Salzen
DE2037586C3 (de) * 1970-07-29 1980-05-22 Henkel Kgaa, 4000 Duesseldorf Gipsmassen
DE2104476C2 (de) * 1971-02-01 1983-12-01 Henkel KGaA, 4000 Düsseldorf Verfahren zur Verhinderung von Ausfällungen in Wasser oder wäßrigen Lösungen
DE3540150A1 (de) * 1985-11-13 1987-05-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
CA1339805C (en) * 1988-01-20 1998-04-07 Yasuo Isomura (cycloalkylamino)methylenebis(phosphonic acid) and medicines containing the same as an active
JPH01231980A (ja) * 1988-03-10 1989-09-18 Ishikawajima Harima Heavy Ind Co Ltd 管内作業用ピグ

Also Published As

Publication number Publication date
CN1022630C (zh) 1993-11-03
KR890011601A (ko) 1989-08-21
DK24389D0 (da) 1989-01-20
AU2867089A (en) 1989-07-20
CA1339805C (en) 1998-04-07
ES2032105T3 (es) 1993-01-01
DE68901097D1 (de) 1992-05-07
IE890183L (en) 1989-07-20
AU615711B2 (en) 1991-10-10
HU202243B (en) 1991-02-28
US4970335A (en) 1990-11-13
ATE74361T1 (de) 1992-04-15
DK174744B1 (da) 2003-10-13
EP0325482A1 (en) 1989-07-26
PH26819A (en) 1992-11-05
DK24389A (da) 1989-07-21
KR970005179B1 (ko) 1997-04-14
HUT50841A (en) 1990-03-28
US5041428A (en) 1991-08-20
EP0325482B1 (en) 1992-04-01
IE60477B1 (en) 1994-07-13
CN1035829A (zh) 1989-09-27

Similar Documents

Publication Publication Date Title
GR3004461T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP0369627A3 (en) Pyrimidinedione derivative compounds, method of producing the same and antiarrythmic agents containing the same
YU142188A (en) Process for preparing polyethylenglycolcarbaminates
HUT49860A (en) Process for producing benzamide-type protease inhibitors
ATE61374T1 (de) Diaminoandrostanderivate.
GR3004018T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU198015A (en) Process for producing 1-substituted-oxindol-3-carboxamid derivatives
DE68909170D1 (de) Serin-Analoge von BU-3608-Antibiotika.
DE68916847D1 (de) Monopersulfate von Amino-(poly)percarbonsäuren.
DE3372364D1 (en) 1-carboxyalkanoylperhydroindole-2-carboxylic acids and derivatives
NO944617D0 (no) Desferrioksamin-B-salter
ES8607935A1 (es) Un procedimiento de preparar un derivado de ariltio-piridi- nil-alcanol
GR3007465T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES2068407T3 (es) Tratamiento de apneas durante el sueño con derivados de azapirona.
GR3005886T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY102760A (en) New surfactants.
EP0206624A3 (en) Diperoxy acids and bleaching therewith
ATE77744T1 (de) Verwendung von pyrrothinderivaten.
GR3005058T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP0373881A3 (en) Process for preparing optically active 2-oxoimidazolidine derivatives
EP0394840A3 (de) 4- Hydroperoxi-2-alkensäuren und deren Ester
IT1217648B (it) Alfa gliceril difosfato di colina,procedimento per la sua preparazione,formulazioni farmaceutiche a suo uso terapeutico
IT1216006B (it) 1,2_di_0_acetil_glicero_3:(difosforil) colina procedimento per la sua preparazione e suo uso terapeutico.
IT1216004B (it) (2_0_acetil glicerolo_3_difosforil) colina procedimento per la sua preparazione e suo uso terapeutico.
IT1215878B (it) Fosforil) colina, procedimento per(1,2 di o acetil glicero 3la sua preparazione e suo uso terapeutico.